PRIME MEMBER EXCLUSIVE | 3 Months Free Trial
Auto-renews at INR 199/mo after 3 months. Cancel anytime. Offer ends 15 July, 2026.
GLP-1 Crackdown: What the FDA Really Means & Why Compounding Still Matters
Failed to add items
Add to cart failed.
Add to wishlist failed.
Remove from wishlist failed.
Follow podcast failed
Unfollow podcast failed
GLP-1 Crackdown: What the FDA Really Means & Why Compounding Still Matters
-
Narrated by:
-
Written by:
There’s been a lot of noise lately around semaglutide, tirzepatide, and other GLP-1 medications—especially as the FDA cracks down on certain compounded versions. But what’s really going on? And what should patients and providers know?
In this solo episode, I unpack the truth behind the headlines. We’ll clarify what GLP-1 medications actually are (hint: they’re not insulin), why they’re in such high demand, and how compounding pharmacies legally stepped in during national shortages. I’ll also break down the difference between 503A and 503B pharmacies and share how to spot quality in compounded meds.
Whether you’re a patient, provider, or pharmacy pro, this episode clears the fog around GLP-1s and gives you real tools to stay informed.